Whooping cough vaccination in adolescents and adults;Vacunación frente a la tos ferina en el adolescente y el adulto

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 1, 2008, Pages 12-19

  Campins Martí, Magda ^a,b   Moraga Llop, Fernando A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b C/ Doctor Roux   (Spain)

Author keywords

Adolescents; Adults; DTaP vaccine; Pertussis; Pertussis vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE; TRIPACEL;

BORDETELLA PERTUSSIS; DRUG EFFICACY; HUMAN; IMMUNIZATION; INCIDENCE; PERTUSSIS; PREVALENCE; REVIEW; VACCINATION;

EID: 45149089215     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13123263     Document Type: Article

References (67)

1. Global Programme on Vaccines. State of the World's Vaccines and Immunization. Genève: World Health Organization; New York: UNICEF; 1996.
2. Campins Martí M, Moraga Llop FA. Vacuna antipertussis. En: Salleras L, editor. Vacunaciones preventivas. Principios y aplicaciones. Barcelona: Masson; 2003. p. 139-61.
3. Servei de Vigilància Epidemiològica de la Direcció General de Salut Pública. Resultats del programa pilot de vigilància de la tos ferina a Catalunya. Butlletí Epidemiològic de Catalunya. 2005;26:1-8.
4. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. En: Atkinson W, Hamborsky J, McIntyre L, Wolfe S, editors. 10th ed. Washington DC: Public Health Foundation; 2007.
5. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999;28:1230-7.
6. Centers for Disease Control and Prevention. Pertussis: United States, 1997-2000. MMWR. 2002;51:73-6.
7. Bass JW, Wittler RR. Return of epidemic pertussis in the United States. Pediatr Infect Dis J. 1994;13:343-5.
8. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE. Resurgence of pertussis in Europe. Pediatr Infect Dis J. 2005;24:761-5.
9. Campins-Martí M, Cheng HK, Forsyth K, et al. Recommendations are needed for adolescent and adult pertussis immunization: rationale and strategies for consideration. Vaccine. 2001;20:641-6.
10. Galanis E, King AS, Varughese P, Halperin SA. Changing epidemiology and emerging risk groups for pertussis. Can Med Assoc J. 2006;174:451-2.
11. Biellik RJ, Patriarca PA, Mullen JR, et al. Risk factors for community-and household-acquired pertussis during a large-scale outbreak in central Wisconsin. J Infect Dis. 1988;157:1134-41.
12. World Healh Organization (WHO). Regional Office for Europe. Health 21: the health for all policy framework for the WHO European Region. Genève: WHO; 1999. European Health for All Series No. 6.
13. Área de Vigilancia Epidemiológica. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Comentario epidemiológico de las Enfermedades de Declaración Obligatoria y Sistema de Información Microbiológica. España. Año 2000. Bol Epidemiol Semanal. 2001;9:101-7.
14. Pachón del Amo I. Impacto de los programas de vacunación en España. Aten Primaria. 2005;35:314-7.
15. Pizarro A, Pachón I. Situación actual de tétanos y tos ferina. Bol Epidemiol Semanal. 1998;6:300-3.
16. Instituto de Salud Carlos III. Servicio de Vigilancia Epidemiológica. Situación de las enfermedades de declaración obligatoria. España. Año 2006. Disponible en: http://www.isciii.es/jsps/centros/epidemiologia/seriesTemporalesAnuales.jsp
17. Servei de Vigilància Epidemiològica de la Direcció de Salut Pública. Resultats del programa pilot de vigilància de la tos ferina a Cataluya. Butlletí Epidemiològic de Catalunya. 2005;26:1-8.
18. Moraga F, Roca, J, Méndez C, et al. Epidemiology and surveillance of pertussis among infants in Catalonia, Spain, during 1997-2001. Pediatr Infect Dis J. 2005;24:510-3.
19. Gil A, Oyaguez I, Carrasco P, González A. Hospital admissions for pertussis in Spain, 1995-1998. Vaccine. 2001;19:4791-4.
20. Jenkinson D. Duration of effectiveness of pertussis vaccine. BMJ. 1988;286:612-4.
21. Moraga Llop FA, Campins Martí M. Tos ferina: ¿conocemos su incidencia real y cómo controlarla? En: Campins Martí, Moraga Llop FA, editors. Vacunas 2005. Barcelona: Prous Science; 2005. p. 9-23.
22. Heininger U, Schmidt-Schlapfer G, Cherry JD, Stehr K. Clinical validation of polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine eficacy trial. Pediatrics. 2000;105:31E.
23. Nennig ME, Shinefield HR, Edwards KM, Black SB, Fireman BH. Prevalence and incidence of adult pertussis in an urban population. JAMA. 1996;275:1672-4.
24. Rosenthal S, Strebel P, Cassiday P, Sanden G, Brusuelas K, Wharton M. Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis. 1995;171:1650-2.
25. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA. 1995;273:1044-6.
26. Cromer BA, Goydos J, Hackell J, et al. Unrecognized pertussis infection in adolescents. Am J Dis Child. 1993;147:575-7.
27. Robertson PW, Goldberg H, Jarvie BH, Smith DD, Whybin LR. Bordetella pertussis infection. Med J Aust. 1987;147:522-5.
28. Mink CM, Cherry JD, Christenson P. A search for Bordetella pertussis infection in university students. Clin Infect Dis. 1992;14:464-71.
29. Schmitt-Grohe S, Cherry JD, Heininger U. Pertussis in German adults. Clin Infect Dis. 1995;21:860-6.
30. Birkebaek NH, Kristiansen M, Seefeldt T, Degn J, Moller A, Heron I, et al. Bordetella pertussis and chronic cough in adults. Clin Infect Dis. 1999;29:1239-42.
31. Senzilet LD, Halperin SA, Spika JS, Alagarantnam M, Morris A, Smith B; SHUSS Pertussis Working Group. Pertussis is a frequent cause of prollonged cough illness in adults and adolescents. Clin Infect Dis. 2001;32:1691-7.
32. Wirsing von König CH, Postels-Multani S, Bock HL, Schmitt HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet. 1995;346:1326-9.
33. Aoyama T, Takeuchi Y, Goto A, Iwai H, Murase Y, Iwata T. Pertussis in adults. Am J Dis Child. 1992;146:163-6.
34. Nelson JD. The changing epidemiology of pertussis in young infants: the role of adults as reservoirs of infection. Am J Dis Child. 1978;132:371-7.
35. Storsaeter J, Blackwelder WC, Hallander HO. Pertussis antibodies, protection and vaccine efficacy after household exposure. Am J Dis Child. 1992;146:167-72.
36. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis. 1990;161:480-6.
37. Biellik RJ, Patriarca PA. Risk factors for community, and household, acquired pertussis during a large-scale outbreak in central Wisconsin. J Infect Dis. 1988;157:1134-41.
38. Baron S, Njankepo E, Grimprel E, Begue P, Desenclos JC, Drucker J, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J. 1998;17:412-8.
39. García M, Campins M, Roca J, Moraga F, Baquero F, Gené A, et al. Bordetella pertussis infection in infants and their household contacts. 4th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). Varsovia (Polonia), september 1-4, 2005 [abstract book, page 49].
40. Kowalkiz F, Barbosa AP, Fernández VR, Carvalho PR, Ávila-Agüero ML, Goh DYT, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Ped Infect Dis J. 2007;26:238-42.
41. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis. Who was the source? Pediatr Infect Dis J. 2004;23:985-9.
42. Aoyama T, Takeuchi Y, Goto A, Iwai H, Murase Y, Iwata T. Pertussis in adults. Am J Dis Child. 1992;146:163-6.
43. Campins Martí M, Moraga Llop FA. Acellular pertussis vaccines for use among infants and young children. Expert Opin Pharmacother. 2004;5:807-17.
44. Van Damme P, Joossens E, Vellinga A, Vanderwielen M, Ramalho A, Kaufhold A. A diphtheria-tetanus-acellular pertussis (dTpa) vaccine for adults. Clin Infect Dis. 1998;27:1053.
45. Keitel W, Edwards K, Englund J, et al. Dose-response comparisons of 5 acellular pertussis vaccines in healthy adults [abstract 286]. Clin Infect Dis. 1996;23:912.
46. Tran Minh NN, Edelman K, He Q, Viljanen MK, Arvilommi H, Mertsola J. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children. Vaccine. 1998;16:1604-10.
47. Van der Wielen M, Van Damme P, Joosens E, François G, Meurice F, et al. A randomised controlled trial with a diphteria-tetanus acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000;18:2075-82.
48. Bartels I, Jungert J, Lugauer S, Stehr K, Heininger Ll. Immunogenicity and reactogenicity of a single dose of a diphteria-tetanus-acellular pertussis component vaccine (DtaP) compared to a diphteria-tetanus toxoid (Td and a diphteria toxoid vaccine (d) in adults. Vaccine. 2000;19:3137-45.
49. McIntyre PF, Turnbull FM, Egan AM, Burgess MA, Wolter JM, Schuerman LM. High levels of antibody in adults three years after vaccination with a reduced antigen content diphteria-tetanus-acellular pertussis vaccine. Vaccine. 2004;23:380-5.
50. Le T, Cherry JD, Chang SJ, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004;190:535-44.
51. Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr. 2006;149:603-10.
52. SmithKline Beecham Biologicals. dTpa combined diphtheria, tetanus, acellular pertussis vaccine. Aplication for a marketing authorisation of a medical product to a competent authority. Part I.C.3. Expert Report. Data on file.
53. Halperin SA, Smith B, Russell M, Scheifele D, Mills E, Hasselback P, et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J. 2000;19:276-83.
54. Ward J; APERT Study Group. Pertussis epidemiology and acellular pertussis vaccine efficacy in older children: NIH APERT Multicenter Pertussis Trial [abstract 1369]. Chicago: ICCAC; 2002. p. 240A.
55. Ward JI, Cherry JD, Chang S-J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555-63.
56. Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as Assessed in a National Prospective Randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis. 2006;43:151-7.
57. Centres for Disease Control. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55:1-44.
58. Centres for Disease Control. Preventing Tetanus, Diphtheria, and Pertussis Among Adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR. 2006;55:1-37.
59. Forsyth KD, Campins-Martí M, Caro J, Cherry JD, Greenberg D, Guiso N, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis. 2004;39:1802-9.
60. Halperin SA, Sweet L, Baxendale D, Neatby A, Rykers P, Smith B, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J. 2006;25:195-200.
61. Ministerio de Sanidad y Consumo. Coberturas de Vacunación. Datos estadísticos (1992-2005). Disponible en: http://www.msc.es/diseno/ paginaImprimir.html
62. Salmasso S. Pertussis vaccine schedules across Europe. Eurosurveillance Weekly 2004;8:7/10/2004. Disponible en: http://www.eurosurveillance.org/ew/2004/ 041007.asp?6.
63. Advisory Committee on Immunization Practices. ACIP recommends adolescent vaccination for tetanus, diphtheria and pertussis vaccine. June 30, 2005. Disponible en: http://www.cdc.gov/nip
64. Comité Asesor de Vacunas de la Asociación Española de Pediatría. Calendario vacunal de la Asociación Española de Pediatría: recomendaciones 2005. An Pediatr (Barc). 2005;62:158-60.
65. Wirsing von König CH, Campins-Martí M, Finn A, Guiso N, Mertsola J, Liese J. Pertussis immunization in the global pertussis initiative European Region. Recommended strategies and implermentation considerations. Pediatr Infect Dis J. 2005;24:87S-92S.
66. Forsyth K, Nagai M, Lepetic A, Trindade E. Pertussis immunization in the global pertussis initiative International Region. Recommended strategies and implermentation considerations. Pediatr Infect Dis J. 2005;24:93S-7S.
67. Salleras L, Bayas JM, Calbo F, Campins M, Castrodeza J, Cerrillo A, et al. Vacunación anti tos ferina de los adolescentes y adultos. Puesta al día. Vacunas. 2007;1:38-47.